Suppr超能文献

一种用于评估实体瘤疾病范围的术前和术中分子成像与检测概念。

A Concept for Preoperative and Intraoperative Molecular Imaging and Detection for Assessing Extent of Disease of Solid Tumors.

作者信息

Hitchcock Charles L, Chapman Gregg J, Mojzisik Cathy M, Mueller Jerry K, Martin Edward W

机构信息

Department of Pathology, College of Medicine, The Ohio State University, Columbus, OH, United States.

Actis Medical, LLC, Powell, OH, United States.

出版信息

Oncol Rev. 2024 Jul 25;18:1409410. doi: 10.3389/or.2024.1409410. eCollection 2024.

Abstract

The authors propose a concept of "systems engineering," the approach to assessing the extent of diseased tissue (EODT) in solid tumors. We modeled the proof of this concept based on our clinical experience with colorectal carcinoma (CRC) and gastrinoma that included short and long-term survival data of CRC patients. This concept, applicable to various solid tumors, combines resources from surgery, nuclear medicine, radiology, pathology, and oncology needed for preoperative and intraoperative assessments of a patient's EODT. The concept begins with a patient presenting with biopsy-proven cancer. An appropriate preferential locator (PL) is a molecule that preferentially binds to a cancer-related molecular target (i.e., tumor marker) lacking in non-malignant tissue and is the essential element. Detecting the PL after an intravenous injection requires the PL labeling with an appropriate tracer radionuclide, a fluoroprobe, or both. Preoperative imaging of the tracer's signal requires molecular imaging modalities alone or in combination with computerized tomography (CT). These include positron emission tomography (PET), PET/CT, single-photon emission computed tomography (SPECT), SPECT/CT for preoperative imaging, gamma cameras for intraoperative imaging, and gamma-detecting probes for precise localization. Similarly, fluorescent-labeled PLs require appropriate cameras and probes. This approach provides the surgeon with real-time information needed for R0 resection.

摘要

作者提出了一种“系统工程”的概念,即评估实体瘤中病变组织范围(EODT)的方法。我们基于对结直肠癌(CRC)和胃泌素瘤的临床经验对这一概念进行了验证,其中包括CRC患者的短期和长期生存数据。这一适用于各种实体瘤的概念,整合了术前和术中评估患者EODT所需的外科、核医学、放射学、病理学和肿瘤学等方面的资源。该概念始于一名经活检证实患有癌症的患者。合适的优先定位剂(PL)是一种优先结合非恶性组织中缺乏的癌症相关分子靶点(即肿瘤标志物)的分子,是关键要素。静脉注射后检测PL需要用合适的示踪放射性核素、荧光探针或两者对PL进行标记。示踪剂信号的术前成像需要单独使用分子成像模态或与计算机断层扫描(CT)联合使用。这些包括正电子发射断层扫描(PET)、PET/CT、单光子发射计算机断层扫描(SPECT)、用于术前成像的SPECT/CT、用于术中成像的伽马相机以及用于精确定位的伽马探测探针。同样,荧光标记的PL需要合适的相机和探针。这种方法为外科医生提供了R0切除所需的实时信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88d6/11306801/e4024987e4ce/or-18-1409410-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验